Complementary and Alternative Medicine During HIV Infection

  • Milena Nasi
  • Marcello Pinti
  • Leonarda Troiano
  • Andrea Cossarizza
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 546)


According to the Joint United Nations Program of HIV/AIDS (UNAIDS) and the World Health Organization (WHO) (Joint United Nations Program of HIV/AIDS, 2001), as of the end of 2001, there were about 40 million adults and children living with human immunod-eficiency virus (HIV) infection. This total does not include the 20 million people around the world who already died of AIDS. Of the 40 million currently alive, 37.2 are adults, 17.6 are women, and more than 2.7 are children. In 2001, there were 5 million new cases of HIV infection in the world, and 3 million AIDS related deaths. The large majority (almost three quarters) live in Sub-Saharan Africa where the prevalence rate of the infection among adults is 8.4%; more than 55% of infected individuals are women. The second major pocket of HIV infection is in South and Southeast Asia, with more than 6 million people infected. In North America where the epidemic was first described, there are 940,000 individuals who are HIV- , and in Western Europe, 540,000. Furthermore, South America, China, and East-ern Europe are characterized by a rapid increase in infection rates. These dramatic numbers clearly indicate that the fight against HIV/AIDS is an absolute health, social, economical and political priority in all parts of the world.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Alternative Medicine Pneumocystis Carinii Pneumonia Joint United Nations Program 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. S. Gottlieb, R. Schroff, H. M. Schanker, J. D. Weisman, P. T. Fan, R. A. Wolf and A. Saxon, Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305(24), 1425–31 (1981).PubMedCrossRefGoogle Scholar
  2. 2.
    M. Louie and M. Markowitz, Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antiviral Res 55(1), 15–25 (2002).PubMedCrossRefGoogle Scholar
  3. 3.
    J. W. Mellors, C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd and L. A. Kingsley, Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272(5265 ), 1167–70 (1996).PubMedCrossRefGoogle Scholar
  4. 4.
    T. S. Li, R. Tubiana, C. Katlama, V. Calvez, H. Ait Mohand and B. Autran, Long-lasting recovery in CD4 T- cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351(9117), 1682–6 (1998).PubMedCrossRefGoogle Scholar
  5. 5.
    G. Ippolito, V. Galati, D. Serraino and E. Girardi, The changing picture of the HIV/AIDS epidemic. Ann N YAcad Sci 946, 1–12 (2001).CrossRefGoogle Scholar
  6. 6.
    C. Mussini, P. Pezzotti, A. Govoni, V. Borghi, A. Antinori, A. d’Arminio Monforte, A. De Luca, N. Mongiardo, M. C. Cerri, F. Chiodo, E. Concia, L. Bonazzi, M. Moroni, L. Ortona, R. Esposito, A. Cos-sarizza and B. De Rienzo, Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 181(5), 1635–42 (2000).PubMedCrossRefGoogle Scholar
  7. 7.
    C. Mussini, P. Pezzotti, A. Antinori, V. Borghi, A. Monforte, A. Govoni, A. De Luca, A. Ammassari, N. Mongiardo, M. C. Cerri, A. Bedini, C. Beltrami, M. A. Ursitti, T. Bini, A. Cossarizza and R. Esposito, Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 36(5), 645–51 (2003).PubMedCrossRefGoogle Scholar
  8. 8.
    R. P. van Heeswijk, A. Veldkamp, J. W. Mulder, P. L. Meenhorst, J. M. Lange, J. H. Beijnen and R. M. Hoetelmans, Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6(4), 201–29 (2001).PubMedGoogle Scholar
  9. 9.
    M. John, D. Nolan and S. Mallal, Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 6(1), 9–20 (2001).PubMedGoogle Scholar
  10. 10.
    J. Borkan, J. O. Neher, O. Anson and B. Smoker, Referrals for alternative therapies. J Fam Pract 39(6), 545–50 (1994).PubMedGoogle Scholar
  11. 11.
    A. Sparber, J. C. Wootton, L. Bauer, G. Curt, D. Eisenberg, T. Levin and S. M. Steinberg, Use of complemen-tary medicine by adult patients participating in HIV/AIDS clinical trials. J Altern Complement Med 6(5), 415–22 (2000).PubMedCrossRefGoogle Scholar
  12. 12.
    B. R. Bates, P. Kissinger and R. E. Bessinger, Complementary therapy use among HIV-infected patients. AIDS Patient Care STDS 10(1), 32–6 (1996).PubMedCrossRefGoogle Scholar
  13. 13.
    J. T. Dwyer, A. M. Salvato-Schille, A. Coulston, V. A. Casey, W. C. Cooper and W. D. Selles, The use of unconventional remedies among HIV-positive men living in California. J Assoc Nurses AIDS Care 6(1), 17–28 (1995).PubMedCrossRefGoogle Scholar
  14. 14.
    R. M. Greenblatt, H. Hollander, J. R. McMaster and C. J. Henke, Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments. J Acquir Immune Defic Syndr 4(2), 136–43 (1991).PubMedGoogle Scholar
  15. 15.
    C. Rowlands and W. G. Powderly, The use of alternative therapies by HIV-positive patients attending the St. Louis AIDS Clinical Trials Unit. Mol Med 88(12), 807–10 (1991).Google Scholar
  16. 16.
    D. M. Eisenberg, R. B. Davis, S. L. Ettner, S. Appel, S. Wilkey, M. Van Rompay and R. C. Kessler, Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280(18), 1569–75 (1998).PubMedCrossRefGoogle Scholar
  17. 17.
    L. J. Standish, K. B. Greene, S. Bain, C. Reeves, F. Sanders, R. C. Wines, P. Turet, J. G. Kim and C. Calabrese, Alternative medicine use in HIV-positive men and women: demographics, utilization patterns and health status. AIDS Care 13(2), 197–208 (2001).PubMedCrossRefGoogle Scholar
  18. 18.
    E. Ernst, The dark side of complementary and alternative medicine. Int J STD AIDS 13(12), 797–800 (2002).PubMedCrossRefGoogle Scholar
  19. 19.
    E. Ernst, “Alternative” medicine and science—like fire and water? Wien Klin Wochenschr 114(15–16), 655–6 (2002).PubMedGoogle Scholar
  20. 20.
    M. Hennessy, D. Kelleher, J. P. Spiers, M. Barry, P. Kavanagh, D. Back, F. Mulcahy and J. Feely, St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53(1), 75–82 (2002).PubMedCrossRefGoogle Scholar
  21. 21.
    E. Ernst and J. Barnes, Meta-analysis of homoeopathy trials. Lancet 351(9099), 366; author reply 367–8 (1998).PubMedCrossRefGoogle Scholar
  22. 22.
    E. Ernst, A systematic review of systematic reviews of homeopathy. Br J Clin Pharmacol 54(6), 577–82 (2002).PubMedCrossRefGoogle Scholar
  23. 23.
    E. Ernst and M. H. Pittler, Re-analysis of previous meta-analysis of clinical trials of homeopathy. J Clin Epidemiol 53(11), 1188. (2000).PubMedCrossRefGoogle Scholar
  24. 24.
    R. Power, C. Gore-Felton, M. Vosvick, D. M. Israelski and D. Spiegel, HIV: effectiveness of complementary and alternative medicine. Prim Care 29(2), 361–78 (2002).PubMedCrossRefGoogle Scholar
  25. 25.
    E. Ottaviani, E. Caselgrandi, M. Bondi, A. Cossarizza, D. Monti & C. Franceschi. The “immuno-mobile” brain: evolutionary evidence. Adv. Neuroimmunol. 1(1), 27–39 (1991).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Milena Nasi
  • Marcello Pinti
  • Leonarda Troiano
  • Andrea Cossarizza
    • 1
  1. 1.Dept. of Biomedical Sciences, Section of General PathologyUniversity of Modena and Reggio EmiliaModenaItaly

Personalised recommendations